Destiny Pharma announces Brazilian Patent granted for XF-73 nasal gel

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma Announces Brazilian Patent Granted for XF-73 nasal gel preventing post-surgical infections Brighton, United Kingdom – 3rd February 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening […]

Destiny Pharma appoints Professor Mark Wilcox to Scientific Advisory Board

Link to Full Article Destiny Pharma plc (“Destiny Pharma” or “the Company”) Destiny Pharma plc strengthens its Scientific Advisory Board with the appointment of Professor Mark Wilcox A recognised leader in UK/NHS infection prevention and control, and a renowned expert in C. difficile infection Brighton, United Kingdom – 2 February 2021 – Destiny Pharma Plc (AIM: […]

Destiny Pharma Phase 2b trial of XF-73 completes recruitment

Link to Full Article Phase 2b clinical trial of XF-73 completes patient recruitment   Results expected in Q1 2021 Brighton, United Kingdom – 5th January 2021 – Destiny Pharma plc (AIM: DEST), a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, today announces that its XF-73 […]

Destiny Pharma Update on the recently acquired NTCD-M3 biotherapeutic clinical programme for prevention of recurrence of C. difficile infections

Link to Full Article Brighton, United Kingdom – 22 December 2020: Destiny Pharma plc (AIM: DEST) a clinical stage innovative biotechnology company focused on the development of novel medicines that can prevent life threatening infections, announces it is making good progress with preparations for the clinical development of NTCD-M3, a Phase 3 ready biotherapeutic for the […]

Destiny Pharma – Result of General Meeting and Total Voting Rights

Link to Full Article Destiny Pharma plc  (“Destiny” or the “Company”) Result of General Meeting  and Total Voting Rights  Brighton, United Kingdom ‐ 26 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that, at the General Meeting held earlier […]

Destiny Pharma announces total gross proceeds raised via Open Offer

Link to Full Article Destiny Pharma plc (“Destiny” or the “Company”) Result of Open Offer Brighton, United Kingdom ‐ 25 November 2020: Destiny Pharma plc (AIM:DEST) a clinical stage biotechnology company focused on the development of novel products to prevent life threatening infections, announces that it has conditionally raised total gross proceeds of approximately £0.87m […]

Destiny Pharma Clinical Study Patient Recruitment Update

Link to Full Article 101 patients recruited in Phase 2b clinical study of lead asset XF-73 for the prevention of postsurgical infections Recruitment on track to complete by year-end and report results in Q1 2021 Brighton, United Kingdom – 12 October 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the […]

Destiny Pharma Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections

Link to Full Article Update on Phase 2b clinical study of lead asset XF-73 in the prevention of post-surgical infections Recruitment on track to complete by year-end and report results in early 2021 Brighton, United Kingdom – 17 September 2020 – Destiny Pharma plc (AIM: DEST), a clinical stage biotechnology company focused on the development of […]

Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19

Link to Full Article Destiny Pharma and SporeGen® announce collaboration and Innovate UK grant award to co-develop novel, preventative treatment for COVID-19 SPOR-COV™ prophylactic approach targets the innate immune system with potential to develop COVID-19 protection within a few days of treatment Innovate UK grant of £800,000 to support SPOR-COV™ programme over the next 18 months […]

Destiny Destiny Pharma welcomes NBIC #BiofilmAware campaign, launched today

Link to Full Article Destiny Pharma, as an NBIC industrial partner, is currently working on three NBIC funded research projects in collaboration with expert teams at the Universities of Cardiff, Sheffield and Southampton. The XF drug platform has demonstrated efficacy against bacteria in biofilms and we are looking forward to advancing these research assets towards […]